- Report
- July 2024
- 120 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- February 2024
- 131 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- February 2024
- 114 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- February 2024
- 114 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- April 2023
- 110 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- February 2024
- 148 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- February 2024
- 110 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- February 2024
- 113 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- April 2023
- 110 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- June 2025
- 250 Pages
Saudi Arabia
From €2443EUR$2,789USD£2,120GBP
- Report
- June 2025
- 250 Pages
Mexico
From €2443EUR$2,789USD£2,120GBP
- Report
- June 2025
- 250 Pages
Vietnam
From €2443EUR$2,789USD£2,120GBP
- Report
- June 2025
- 250 Pages
Brazil
From €2443EUR$2,789USD£2,120GBP
- Report
- June 2025
- 250 Pages
Japan
From €2443EUR$2,789USD£2,120GBP
- Report
- May 2023
- 147 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- May 2023
- 147 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- March 2024
- 147 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- December 2022
- 316 Pages
Global
From €3153EUR$3,600USD£2,737GBP
- Report
- December 2022
- 107 Pages
Africa, Middle East
From €1314EUR$1,500USD£1,140GBP
- Report
- December 2022
- 109 Pages
Asia Pacific
From €1314EUR$1,500USD£1,140GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more